Citigroup’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.3M Buy
388,087
+34,108
+10% +$1.4M 0.01% 1135
2026
Q1
$11.8M Sell
353,979
-129,546
-27% -$3.86M 0.01% 1373
2025
Q4
$14.4M Sell
483,525
-263,394
-35% -$8.6M 0.01% 1295
2025
Q3
$27M Buy
746,919
+60,897
+9% +$2.01M 0.01% 907
2025
Q2
$24.7M Buy
686,022
+336,918
+97% +$12.5M 0.01% 869
2025
Q1
$13.8M Buy
349,104
+1,927
+0.6% +$64.8K 0.01% 1167
2024
Q4
$10.5M Buy
347,177
+178,900
+106% +$5.13M 0.01% 1349
2024
Q3
$3.94M Buy
168,277
+93,730
+126% +$2.05M ﹤0.01% 2055
2024
Q2
$1.33M Sell
74,547
-454,022
-86% -$7.24M ﹤0.01% 2687
2024
Q1
$8.04M Buy
528,569
+163,225
+45% +$2.6M 0.01% 1379
2023
Q4
$6.24M Sell
365,344
-67,993
-16% -$790K ﹤0.01% 1456
2023
Q3
$3.62M Buy
433,337
+233,650
+117% +$3.26M ﹤0.01% 1603
2023
Q2
$4.96M Sell
199,687
-253,615
-56% -$6.55M ﹤0.01% 1492
2023
Q1
$6.82M Buy
453,302
+22,351
+5% +$340K ﹤0.01% 1330
2022
Q4
$5.1M Sell
430,951
-640,001
-60% -$4.65M ﹤0.01% 1467
2022
Q3
$6.34M Buy
1,070,952
+294,444
+38% +$1.93M ﹤0.01% 1410
2022
Q2
$3.3M Buy
776,508
+675,007
+665% +$4.21M ﹤0.01% 1766
2022
Q1
$966K Sell
101,501
-410,320
-80% -$4.75M ﹤0.01% 3002
2021
Q4
$9.72M Buy
511,821
+430,157
+527% +$11.2M 0.01% 1396
2021
Q3
$2.72M Sell
81,664
-33,757
-29% -$1.04M ﹤0.01% 2297
2021
Q2
$4.48M Buy
115,421
+24,114
+26% +$947K ﹤0.01% 1994
2021
Q1
$4.4M Buy
91,307
+66,861
+274% +$3.21M ﹤0.01% 1873
2020
Q4
$1.27M Buy
24,446
+2,836
+13% +$95.8K ﹤0.01% 3300
2020
Q3
$578K Sell
21,610
-74,192
-77% -$1.71M ﹤0.01% 3733
2020
Q2
$1.87M Sell
95,802
-2,520
-3% -$40.6K ﹤0.01% 2887
2020
Q1
$967K Sell
98,322
-33,007
-25% -$417K ﹤0.01% 3214
2019
Q4
$1.46M Sell
131,329
-99,941
-43% -$760K ﹤0.01% 3334
2019
Q3
$1.3M Sell
231,270
-110,444
-32% -$770K ﹤0.01% 3341
2019
Q2
$2.96M Buy
341,714
+328,907
+2,568% +$2.49M ﹤0.01% 2417
2019
Q1
$103K Sell
12,807
-495,166
-97% -$2.68M ﹤0.01% 5719
2018
Q4
$2.08M Buy
507,973
+336,978
+197% +$1.67M ﹤0.01% 2626
2018
Q3
$958K Buy
170,995
+71,537
+72% +$817K ﹤0.01% 3548
2018
Q2
$1.31M Buy
99,458
+7,013
+8% +$96.4K ﹤0.01% 3074
2018
Q1
$1.31M Sell
92,445
-36,806
-28% -$470K ﹤0.01% 3011
2017
Q4
$1.06M Buy
129,251
+33,036
+34% +$289K ﹤0.01% 3282
2017
Q3
$1.14M Buy
96,215
+9,703
+11% +$111K ﹤0.01% 3235
2017
Q2
$870K Buy
86,512
+86,163
+24,689% +$964K ﹤0.01% 3459
2017
Q1
$4K Buy
349
+249
+249% +$1.79K ﹤0.01% 6870
2016
Q4
$0 Hold
100
﹤0.01% 7333
2016
Q3
$1K Buy
+100
New +$643 ﹤0.01% 6993
2016
Q2
Sell
-29,273
Closed -$249K 7431
2016
Q1
$249K Buy
29,273
+25,590
+695% +$224K ﹤0.01% 4868
2015
Q4
$44K Sell
3,683
-36,669
-91% -$463K ﹤0.01% 6032
2015
Q3
$407K Buy
40,352
+39,831
+7,645% +$593K ﹤0.01% 3939
2015
Q2
$9K Sell
521
-1,751
-77% -$27.7K ﹤0.01% 6522
2015
Q1
$36K Sell
2,272
-3,102
-58% -$47K ﹤0.01% 5737
2014
Q4
$86K Buy
5,374
+4,557
+558% +$59.3K ﹤0.01% 5353
2014
Q3
$9K Buy
817
+619
+313% +$5.74K ﹤0.01% 6328
2014
Q2
$2K Sell
198
-2,720
-93% -$17.4K ﹤0.01% 6776
2014
Q1
$20K Sell
2,918
-2,327
-44% -$13.8K ﹤0.01% 6030
2013
Q4
$20K Buy
5,245
+4,619
+738% +$18.7K ﹤0.01% 6179
2013
Q3
$3K Sell
626
-85
-12% -$520 ﹤0.01% 6536
2013
Q2
$5K Buy
+711
New +$4.55K ﹤0.01% 6323

Other funds holding TGTX

Citigroup's TGTX Position: Q2 2026 in Review

Citigroup increased its TG Therapeutics (TGTX) stake by 9.6% in Q2 2026, buying an estimated $1.4M and bringing the position to 388,087 shares worth $21.3M. The position accounts for 0.01% of the portfolio, ranked #1135.

Citigroup first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $27M in Q3 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Citigroup held 388,087 shares of TG Therapeutics worth $21.3M as of Q2 2026.
  • Citigroup bought 34,108 TG Therapeutics shares in Q2 2026, an estimated $1.4M.
  • TG Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1135 holding.
  • Citigroup first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's TG Therapeutics position peaked at $27M in Q3 2025.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.